Edition:
United Kingdom

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.77USD
15 Dec 2017
Change (% chg)

$-0.03 (-1.07%)
Prev Close
$2.80
Open
$2.77
Day's High
$2.78
Day's Low
$2.70
Volume
93,007
Avg. Vol
566,378
52-wk High
$8.68
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Celsion reports Q3 loss of $0.70/shr
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.  Full Article

CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Celsion Corp ::CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK.‍PRICING OF OFFERING OF 2.64 MILLION SHARES OF COMMON STOCK, WARRANTS TO BUY UP TO 1.32 MILLION SHARES OF COMMON STOCK AT $2.50/SHARE, RELATED WARRANTS​.  Full Article

Celsion Corp Q2 loss per share $0.79
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - Celsion Corp :Celsion corporation reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.79.Celsion corp - ‍expects to complete enrollment of optima study by mid - 2018.​.  Full Article

Celsion cancels registered direct offering
Thursday, 22 Jun 2017 

June 22 (Reuters) - Celsion Corp ::Celsion Corporation announces cancellation of registered direct offering.Company noted it did not possess ability to register a sufficient number of shares pursuant to form S-3 until July 1, 2017.Company has entered into an agreement with each of investors to terminate offering.Cancelled registered direct offering of common stock announced Monday, June 19.  Full Article

Celsion Corp announces positive DSMB review of Phase 1B ovation study in ovarian cancer
Thursday, 1 Dec 2016 

Celsion Corp : Celsion Corporation announces positive DSMB review of Phase 1B ovation study in ovarian cancer . Celsion - study to continue as planned, co to proceed with completing dosing in fourth and final patient cohort, which is currently enrolling patients. .Celsion Corp - expect to report final data from ovation study C in Q1 of 2017.  Full Article

Celsion posts Q2 loss of $0.19/share
Monday, 15 Aug 2016 

Celsion Corp: Celsion Corporation reports second quarter 2016 financial results and provides business update . Q2 loss per share $0.19 .Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Celsion expects to report translational data from first two cohorts of ovation study in Q3
Tuesday, 24 May 2016 

Celsion Corp : Celsion Corp Says Has Completed Enrollment Of Second Cohort Of Ovation Study And Expects To Report Clinical Data From That Cohort Mid Year . Celsion Corp says also expects to report translational data from first two cohorts of ovation study early in Q3 of 2016 .Celsion announces presentation of ovation study clinical trial design at upcoming asco 2016 meeting.  Full Article

Celsion Corp Q1 loss per share $0.24
Monday, 16 May 2016 

Celsion Corp : Celsion corporation reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.24 .Q1 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update